Enforcement record

特例承認 disclosure naming 中外製薬株式会社

中外製薬株式会社 (Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices)

This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.

Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical DevicesMinistry of Health, Labour and WelfareGovernment disclosure5 November 2021

Action type

特例承認

Law

Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices

Authority

Ministry of Health, Labour and Welfare

Action date

5 November 2021

RegBase evidence report

Japanese public-record enforcement check

Saveable record of the published action, regulator source, source status, and review notes for internal compliance files.

Report ID: RB-EN-ENFORCEMENT-OTHER-ZHONG-WAI-Z-202608182208
Generated at: 19 August 2026 at 07:08
Record URL: https://regbase.jp/en/enforcement/other-zhong-wai-zhi-yao-20211105

1. Review Summary

Disclosure name	中外製薬株式会社	Corporate Number	Not stated in the disclosure
Enforcement record	1 record	Other confirmed records for this company	Outside this report's scope
Action date	5 November 2021	Authority	Ministry of Health, Labour and Welfare
Law	Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices	Action type	特例承認
Source status	Preserved public-source archive recorded

This report summarizes public Japanese government disclosure data held by RegBase. It is not a credit score, sanctions conclusion, legal opinion, or adverse-media determination. Confirm important decisions against the linked official Japanese source.

2. Published Information

Published name	中外製薬株式会社

3. Enforcement Record

Target name in disclosure	中外製薬株式会社
Authority	Ministry of Health, Labour and Welfare (厚生労働省)
Law / action type	Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices / 特例承認
Action / announcement date	Action: 5 November 2021 / Announcement: 27 April 2026
English summary	A special approval was granted under Article 14-3 of the Pharmaceuticals and Medical Devices Act regarding some changes to the manufacturing and marketing approval for a COVID-19 treatment drug.
Original Japanese text	新型コロナウイルス感染症に係る治療薬の製造販売承認事項の一部変更等について、医薬品医療機器等法第14条の３に基づく特例承認を行いました。
Official source	https://www.mhlw.go.jp/stf/newpage_22075.html
Source archive	https://kiroku.today/a/f1354e3de7h5bzf5
Extraction / evidence timestamps	Extracted: 27 April 2026 at 21:01 / Evidence checked: 27 April 2026 at 21:01 / Archive captured: 27 April 2026 at 21:01

4. Business Location and Permit Details

No additional structured business-location or permit fields are recorded for this disclosure.

5. Other Confirmed Records for This Company

This report covers the single government disclosure shown on this page.

Reviewer Notes

Reviewer		Team / company
Review purpose
Additional notes

□ Official source URL or archived source was checked.
□ Corporate Number, address, or other identifiers were reviewed to avoid confusing similarly named entities.
□ This document is understood as a public-record evidence file, not a credit decision or legal opinion.

Current page: Enforcement record

This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.

Free report

Save the disclosure record naming 中外製薬株式会社

Includes the published name, regulator, governing law, source links, archive status, and reviewer note fields for internal due-diligence files.

Preserved evidence by Kiroku

Review the preserved source for 中外製薬株式会社

Open the preserved public source with its capture time, original artifact, available verification data, and downloadable evidence pack.

Open preserved source and evidence pack

For developers: JSON integration details

You do not need this for normal browsing. Use it only when integrating this enforcement record into an internal tool or AI workflow.

/api/v1/enforcements?company=%E4%B8%AD%E5%A4%96%E8%A3%BD%E8%96%AC%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE&limit=10

Open JSON Specs

Action summary

Company: 中外製薬株式会社Japanese only
Original: 中外製薬株式会社
Governing law: Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices
医薬品医療機器等法
Action type: 特例承認
特例承認
Action date: 5 November 2021
Issuing authority: Ministry of Health, Labour and Welfare
厚生労働省
Industry context: 医薬品製造販売

Violation

Machine-translated summary — verify against original

A special approval was granted under Article 14-3 of the Pharmaceuticals and Medical Devices Act regarding some changes to the manufacturing and marketing approval for a COVID-19 treatment drug.

Show original Japanese text

新型コロナウイルス感染症に係る治療薬の製造販売承認事項の一部変更等について、医薬品医療機器等法第14条の３に基づく特例承認を行いました。

Compliance context

Context needed

This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.

Japanese regulatory disclosure under Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices.

Review the original Japanese source and determine relevance to your counterparty-risk workflow.

This context is an operational aid for review workflows, not a credit opinion or legal conclusion.

Evidence pack

Original Ministry of Health, Labour and Welfare source (Japanese)Open preserved source and evidence pack

Extracted at: 2026-04-27T12:01:07.696+00:00
Evidence checked: 2026-04-27T12:01:07.696+00:00
Archive captured: 2026-04-27T12:01:44.598426+00:00

Show audit JSON

{
  "record": {
    "id": "093131aa-10b4-4b98-a53c-e9c997030caa",
    "url": "https://regbase.jp/en/enforcement/other-zhong-wai-zhi-yao-20211105",
    "company_name_original": "中外製薬株式会社",
    "company_name_registry": null,
    "corporate_number": null,
    "law": {
      "ja": "医薬品医療機器等法",
      "en": "Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices"
    },
    "action_type": {
      "ja": "特例承認",
      "en": "特例承認"
    },
    "authority": {
      "ja": "厚生労働省",
      "en": "Ministry of Health, Labour and Welfare"
    }
  },
  "entity_match": {
    "status": "unresolved",
    "confidence": 85,
    "method": "nta_strict_name_nationally_unique",
    "method_label": "nta_strict_name_nationally_unique",
    "notes": "NTA full-download lookup found a nationally unique exact registered-name candidate (中外製薬株式会社). No Corporate Number was present in the disclosure, so this remains a likely match."
  },
  "review": {
    "status": "unreviewed",
    "label": "Machine extracted"
  },
  "compliance_context": {
    "severity": "Context needed",
    "actionMeaning": "This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.",
    "practicalNote": "Review the original Japanese source and determine relevance to your counterparty-risk workflow.",
    "lawContext": "Japanese regulatory disclosure under Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices."
  },
  "evidence": {
    "recordUrl": "https://regbase.jp/en/enforcement/other-zhong-wai-zhi-yao-20211105",
    "officialSourceUrl": "https://www.mhlw.go.jp/stf/newpage_22075.html",
    "officialDocumentUrl": null,
    "archiveUrl": "https://kiroku.today/a/f1354e3de7h5bzf5",
    "archivedSourceUrl": "https://www.mhlw.go.jp/stf/newpage_22075.html",
    "archiveCapturedAt": "2026-04-27T12:01:44.598426+00:00",
    "extractedAt": "2026-04-27T12:01:07.696+00:00",
    "translatedAt": "2026-05-01T09:43:02.242+00:00",
    "evidenceCheckedAt": "2026-04-27T12:01:07.696+00:00",
    "generatedAt": "2026-08-18T22:08:37.233Z"
  },
  "limitations": [
    "RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
    "English summaries are provided for reference. The original Japanese source is authoritative.",
    "Possible or unresolved entity matches should be manually verified before use in a decision."
  ]
}

The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.

Language

日本語版を見る (Japanese)

About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.